
NS Pharma is a biopharmaceutical company that develops and commercializes innovative therapies for rare and complex diseases, drawing on more than a century of expertise from its parent company, Nippon Shinyaku. The firm focuses on genetic disorders such as Duchenne muscular dystrophy and Hunter syndrome, while also addressing hematology, urology, and ENT conditions. Its patient‑centric model—built on close collaboration with patients, caregivers, advocacy groups, and clinicians—helps identify unmet needs and guide the integrated care journey. By acting as a bridge between Japan/Asia and the global market, NS Pharma licenses and markets Japanese‑originated drug candidates worldwide, positioning itself as a unique conduit for cutting‑edge rare‑disease therapeutics.
The Rare Disease Patient Engagement Lead (PEL) is a key field-based member of the Patient Access team, responsible for providing guidance to patients and caregivers on the steps required to gain access to therapy and serving as the primary regional resource for patient advocacy activities.
NS Pharma is a biopharmaceutical company that develops and commercializes innovative therapies for rare and complex diseases, drawing on more than a century of expertise from its parent company, Nippon Shinyaku. The firm focuses on genetic disorders such as Duchenne muscular dystrophy and Hunter syndrome, while also addressing hematology, urology, and ENT conditions. Its patient‑centric model—built on close collaboration with patients, caregivers, advocacy groups, and clinicians—helps identify unmet needs and guide the integrated care journey. By acting as a bridge between Japan/Asia and the global market, NS Pharma licenses and markets Japanese‑originated drug candidates worldwide, positioning itself as a unique conduit for cutting‑edge rare‑disease therapeutics.